Patent intelligence · US
US 8288342
Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
Patent details — US 8288342
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 16, 2012
- Expiration
- Oct 11, 2032
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/21, A61K31/56, A61P
Quick answer
US 8288342 (Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Oct 16, 2012. Expires Oct 11, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/21, A61K31/56, A61P, A61P35/00, A61P5/26
More from TEVA WOMEN'S HEALTH, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8288342?
US 8288342 (Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Oct 16, 2012. Expires Oct 11, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8288342?
TEVA WOMEN'S HEALTH, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8288342 expire?
Our index shows an expiration date of Oct 11, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.